Co-Diagnostics (CODX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 Oct, 2026Executive summary
Court-ordered special meeting follows two 2026 annual-meeting sessions that lacked the then-required majority quorum; the court set a 33⅓% quorum for this meeting and reconvened sessions, without changing approval thresholds.
Nine proposals cover director elections, equity-plan shares, say-on-pay, auditor ratification, future meeting quorum, warrant and note share issuances, reverse splits, and adjournment; the Board unanimously recommends FOR each.
Voting matters and shareholder proposals
Five directors are nominated for one-year terms through the 2027 annual meeting: Dwight Egan, Eugene Durenard, Richard Serbin, James Nelson, and Edward Murphy; election is by plurality.
Proposal 2 seeks 2,000,000 additional 2025 Plan shares, increasing the reserve from 223,333 to 2,223,333; 123,333 shares remained available as of the record date.
Proposal 3 is a non-binding advisory vote on 2025 named executive compensation; the Compensation Committee will consider the result in future pay decisions.
Proposal 4 asks shareholders to ratify Tanner LLC for FY2026; Proposal 5 would set a one-third quorum for future annual and special meetings while leaving substantive voting thresholds unchanged.
Proposals 6–9 seek approval of up to 3,404,724 warrant shares at $1.56, note-related share issuance, reverse splits totaling up to 1-for-750 within 12 months, and meeting adjournment; proposals 2–9 require a majority of votes cast.
Board of directors and corporate governance
The five-member Board has four independent non-employee directors; it met 11 times in 2025, and each director attended more than 75% of applicable Board and committee meetings.
Four standing committees cover audit, compensation, corporate governance, and nominations; Eugene Durenard chairs audit and is designated the audit committee financial expert.
Compensation, governance, and nominating committee matters were handled in Board meetings as needed in 2025; none of those committees met separately that year.
Board nominee review considers experience, education, employment history, skills, participation, geography, and diversity factors; there is no formal diversity policy.
Dwight Egan petitioned for a court-ordered shareholder meeting and reduced quorum; the Board consented, and the court order stated it did not involve allegations of wrongdoing.
Latest events from Co-Diagnostics
- Regulatory progress amid losses, low cash and substantial going-concern doubt.CODX
Q3 2026 - Convertible debt resale registration creates substantial potential dilution without issuer proceeds.CODX
Registration filing - Nine proposals seek equity-plan capacity, financing approvals, a lower quorum and reverse-split authority.CODX
Proxy filing - Approval sought for warrant exercise, reverse stock split, and adjournment authority.CODX
Proxy filing - ReadyGo collaboration and automation drive blood-based testing, rapid outbreak response, and global expansion.CODX
Status update - Annual Meeting adjourned to September 24, 2026; shareholders notified of new date.CODX
Proxy filing - Registering 3.4M shares for resale; up to $5.31M in proceeds possible from warrant exercises.CODX
Registration filing - Net loss narrowed as regulatory milestones advanced and global commercialization expanded.CODX
Q2 2026 - Annual meeting covers director elections, equity plan, pay, auditor, quorum, and adjournment.CODX
Proxy filing